Neuraxis, Inc (NRXS): R&D Expense

Annual figures by period end, from SEC filings.

$493.6K
Year ended 2025-12-31
+29.8%
3-year compound annual growth
2022-12-31: $225.6K2023-12-31: $169.3K2024-12-31: $433.6K2025-12-31: $493.6K$493.6K
2022-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$493.6K+13.8%2026-03-19, From 2025-01-01
2024-12-31$433.6K+156.1%2026-03-19, From 2024-01-01
2023-12-31$169.3K-25.0%2025-03-20, From 2023-01-01
2022-12-31$225.6Kn/a2024-04-16, From 2022-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Electromedical & Electrotherapeutic Apparatus), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Neuraxis, Inc (NRXS)2025-12-31$493.6K+13.8%
ADM Tronics Unlimited, Inc. (ADMT)2026-03-31$545.0K+5.4%
Nuwellis, Inc. (NUWE)2025-12-31$2.71M-15.5%
Escalon Medical Corp (ESMC)2025-06-30$753.1K+9.4%
CapsoVision, Inc (CV)2025-12-31$18.31M+21.1%
Hyperfine, Inc. (HYPR)2025-12-31$17.45M-22.4%
Guided Therapeutics Inc (GTHP)2025-12-31$469.0K-10.8%
QT Imaging Holdings, Inc. (QTI)2025-12-31$3.94M+20.5%
Precision Optics Corporation, Inc. (POCI)2025-06-30$1.16M+17.9%

Compare NRXS, ADMT, NUWE, ESMC side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗